Third People 's Hospital of Liaoyang

Abstract Wind power generation is highly sensitive to meteorological conditions, leading to strong volatility and limited controllability. Accurate short-term wind power forecasting is therefore critical for maintaining power system stability and improving the utilization of renewable energy. In this work, we propose an enhanced forecasting model termed Particle Swarm Optimization Residual Structure Convolutional Neural Network Long Short Term Memory (PR-CNN-LSTM), which extends the conventional CNN-LSTM architecture. The model first employs CNN-LSTM to capture local patterns and temporal dependencies across different forecasting horizons. Residual structures are then introduced into both the convolutional and recurrent modules to stabilize deep network training and enhance representation learning. Furthermore, particle swarm optimization is incorporated to dynamically tune key model hyperparameters, enabling adaptive selection of an optimal parameter configuration. Extensive experiments demonstrate that PR-CNN-LSTM consistently outperforms representative baseline models under all evaluated forecasting scenarios. In single-step forecasting, the proposed model achieves an R 2 exceeding 0.97, indicating strong accuracy and robustness. These results suggest that the proposed approach provides effective technical support for smart grid scheduling, power balance management, and the large-scale integration of wind energy.

Patients' adherence is important for successful Helicobacter pylori (H. pylori) eradication, and may be improved by WeChat, a popular social networking platform. This study aimed to evaluate patients' adherence, successful H. pylori eradication, and clinical remission under the WeChat-based enhanced guidance. Ninety-nine patients with H. pylori infection, who were treated by a 14-day standard bismuth-containing quadruple therapy (BQT) and received the WeChat-based enhanced guidance, were retrospectively included. Multivariate logistic regression analysis was performed to identify independent predictors of patients' adherence and H. pylori eradication. Odds ratios (ORs) were calculated. The rates of good medication adherence, good re-examination adherence, successful H. pylori eradication, and clinical remission were 97.0%, 83.8%, 89.2%, and 89.5%, respectively. Patients with poor re-examination adherence had significantly lower proportions of individual dining (13.3% versus 50.6%, P=0.008) and no smoking during treatment (66.7% versus 92.8%, P=0.012) than those with good re-examination adherence. Both individual dining (OR=0.182, P=0.035) and no smoking during treatment (OR=0.210, P=0.031) were independently associated with good re-examination adherence. Patients with H. pylori eradication failure had significantly higher proportions of poor medication adherence (22.2% versus 1.4%, P=0.030) and living in rural area (44.4% versus 8.1%, P=0.009) than those with H. pylori eradication success. Both poor medication adherence (OR=20.366, P=0.031) and living in rural area (OR=8.944, P=0.010) were independently associated with H. pylori eradication failure. There is good medication adherence with satisfactory H. pylori eradication and clinical remission under the WeChat-based enhanced guidance. How to improve re-examination adherence should be further explored.

Contact lenses were originally designed for cosmetic and vision correction purposes. Recently, they have become mobile wearable devices that integrate drug delivery, diagnosis, and treatment. The portability of contact lenses, the advancement of modern technology, and the public's growing demand for personalized diagnosis and treatment have accelerated the research progress of smart contact lenses. This article summarizes the development trends of smart contact lenses in the diagnosis and treatment of eye diseases, along with future prospects, opportunities, and challenges.

Postpartum depression (PPD) is an extremely common mood disorder that occurs at any time up to 1 year after delivery. PPD can have a negative impact on the mother and family. This study aimed to determine the prevalence of PPD and factors influencing PPD. Specifically, this study focused on the effects of marital quality and mental well-being on PPD and the mediating roles. A cross-sectional study was conducted in the Maternity and Child Health Care Hospitals of Liaoning Province in northeast China. The PHQ-9 scale was used to screen for PPD with a score ≥10, indicating a positive result. The Warwick-Edinburgh Mental Health and Marriage Perception scales were used to evaluate the mental well-being and marital quality of parturients. A total of 1048 participants were included in the study. The prevalence of PPD symptoms was 11.16%. Factors, such as education level (F = 2.63; p < 0.05), co-living status (F = 5.84; p < 0.01), agreement with fetal gender expectations (t = 19.39; p < 0.001), amount of physical activity (F = 17.15; p < 0.001), and knowledge about PPD (t = 3.66; p < 0.001 and t = 5.099; p < 0.001), were all associated with the PPD score and the prevalence. Mental well-being and marital quality were intricately linked to PPD symptoms. Mental well-being influenced PPD via two mediating factors (marital interaction [p < 0.001] and marital conflict [p< 0.001]). PPD is a significant postpartum issue that is influenced by numerous factors. Early screening of parturients, accurate diagnosis of PPD, and timely intervention are crucial. Targeted interventions addressing risk factors may help to mitigate the incidence of PPD.

L-arginine can produce nitric oxide (NO) under the action of inducible nitric oxide synthase (iNOS), while 5-fluorouracil (5-FU) can induce the increase of iNOS expression. The present study was to investigate the mechanism of L-arginine combined with 5-FU regulating glucose metabolism of hepatocellular carcinoma (HCC) through iNOS/NO/AKT pathway. The combination of L-arginine and 5-FU resulted in decreased cell survival and exhibited synergistic cytotoxic effects in HepG2 and SMMC7721 cells. Meanwhile, L-arginine increased 5-FU inhibitory effect on HepG2 and SMMC7721 cells by increasing NO production. Co-treatment with L-arginine and 5-FU resulted in a significant decrease in both G6PDH and LDH enzymatic activities, as well as reduced levels of ATP and LD compared to treatment with L-arginine or 5-FU alone. Moreover, the combination of L-arginine and 5-FU resulted in a decrease in the expression of GLUT1, PKM2, LDHA, p-PI3K and p-AKT. Furthermore, the combination demonstrated a synergistic effect in downregulating the expression of HIF-1α and β-catenin, which were further diminished upon the addition of shikonin, a specific inhibitor of PKM2. LY294002 treatment further reduced the expression of GLUT1, PKM2, and LDHA proteins induced by combined L-arginine and 5-FU treatment compared to the combined group. However, the reduction in p-PI3K, p-AKT, and GLUT1 expression caused by L-arginine and 5-FU combination was also reversed in HepG2 and SMMC7721 cells with iNOS knockdown, respectively. Additionally, the combination of L-arginine and 5-FU led to a greater reduction in the enzymatic activity of ALT, AST, G6PDH and LDH, as well as a significant reduction in hepatic index, AFP, AFP-L3, ATP and LD levels in a rat model of HCC. Moreover, the simultaneous administration of L-arginine and 5-FU significantly improved the gross morphology of the liver, reduced nuclear atypia, inhibited the proliferation of cancer cells, and decreased the expression levels of p-PI3K, p-AKT, GLUT1, PKM2, and LDHA, while iNOS expression was increased in the combination group. Taking together, L-arginine and 5-FU combination resulted in the inhibition of enzymes in aerobic glycolysis via the iNOS/NO/AKT pathway, which led to the suppression of glucose metabolism and downregulation of nuclear transcription factors, thereby impeding the proliferation of hepatocellular carcinoma cells.

Finding reliable and easy-to-obtain predictors of severe infectious complications after shock wave lithotripsy (SWL) is a major clinical need, particular in symptom-free hydronephrosis. Therefore, we aim to prospectively investigate the predictive value of Hounsfield units (HU) in renal pelvis urine for the risk of severe infectious complications in patients with ureteral stones and symptom-free hydronephrosis after SWL. This multi-center prospective study was conducted from June 2020 to December 2023. The HU of renal pelvis urine was measured by non-enhanced computed tomography. The severe infectious complications included systemic inflammatory response syndrome, sepsis, and septic shock. Binary logistic regression models assessed the odds ratios (ORs) and 95% confidence intervals (CIs). Finally, 1,436 patients with ureteral stones were enrolled in this study. 8.9% (128/1,436) of patients experienced severe infectious complications after SWL treatment. After adjusting confounding variables, compared with the patients in the lowest renal pelvis urine density quartile, the OR (95% CI) for the highest quartile was 32.36 (13.32, 78.60). There was a positive linear association between the HU value of renal pelvis urine and the risk of severe infectious complications after SWL (P for trend < 0.001). Furthermore, this association was also observed stratified by age, gender, BMI, stone size, stone location and hydronephrosis grade (all P for interaction > 0.05). Additionally, the nonlinear association employed by restricted cubic splines is not statistically significant (nonlinear P = 0.256). The AUROC and 95%CI of renal pelvis urine density were 0.895 (0.862 to 0.927, P value < 0.001). The cut-off value was 12.0 HU with 78.59% sensitivity and 85.94% specificity. This multi-center prospective study demonstrated a positive linear association between HU in renal pelvis urine and the risk of severe infectious complications in patients with ureteral stones and symptom-free hydronephrosis after SWL, regardless of age, gender, BMI, stone size, stone location, and hydronephrosis grade. These findings might be helpful in the SWL treatment decision-making process.

A series of 20 novel gefitinib derivatives incorporating the 1,2,3-triazole moiety were designed and synthesized. The synthesized compounds were evaluated for their potential anticancer activity against EGFR wild-type human non-small cell lung cancer cells (NCI-H1299, A549) and human lung adenocarcinoma cells (NCI-H1437) as non-small cell lung cancer. In comparison to gefitinib, Initial biological assessments revealed that several compounds exhibited potent anti-proliferative activity against these cancer cell lines. Notably, compounds 7a and 7j demonstrated the most pronounced effects, with an IC50 value of 3.94 ± 0.17 µmol L−1 (NCI-H1299), 3.16 ± 0.11 µmol L−1 (A549), and 1.83 ± 0.13 µmol L−1 (NCI-H1437) for 7a, and an IC50 value of 3.84 ± 0.22 µmol L−1 (NCI-H1299), 3.86 ± 0.38 µmol L−1 (A549), and 1.69 ± 0.25 µmol L−1 (NCI-H1437) for 7j. These two compounds could inhibit the colony formation and migration ability of H1299 cells, and induce apoptosis in H1299 cells. Acute toxicity experiments on mice demonstrated that compound 7a exhibited low toxicity in mice. Based on these results, it is proposed that 7a and 7j could potentially be developed as novel drugs for the treatment of lung cancer.